中国误诊学杂志2012,Vol.12Issue(14) :3447-3449.

缬沙坦对维持性血液透析患者心脏功能和结构的影响

Effect of valsartan on cardiac function and structure in maintenance hemodialysis patients

环文英 王楚凤
中国误诊学杂志2012,Vol.12Issue(14) :3447-3449.

缬沙坦对维持性血液透析患者心脏功能和结构的影响

Effect of valsartan on cardiac function and structure in maintenance hemodialysis patients

环文英 1王楚凤1
扫码查看

作者信息

  • 1. 新疆克拉玛依市中心医院肾病科 834000
  • 折叠

摘要

目的 探讨缬沙坦对维持性血液透析(maintenance hemodialysis,MHD)患者心脏功能和结构的影响.方法 100例MHD患者,随机分为缬沙坦治疗组与对照组,治疗前及治疗后使用超声心动图测定心脏结构指标:左房收缩末期内径(LADs)、左室舒张末期内径(LVEDd)、室间隔舒张末期厚度(IVSTd)、左室后壁舒张末期厚度(LVPWTd),左房内径指数(LAI)、左心室心肌重量指数(LVMI)、相对室壁厚度(RWT);心脏功能指标:左室射血分数(LVEF),左室短轴缩短率(FS),二尖瓣口舒张早期和晚期最大血流速度比(E/A)各项指标测定.结果 治疗组MHD患者心脏结构指标:左房收缩末期内径(LADs)、左室舒张末期内径(LVEDd)、室间隔舒张末期厚度(IVSTd)、左室后壁舒张末期厚度(LVPWTd),左房内径指数(LAD、左心室心肌重量指数(LVMI)值均明显低于对照组,二者差异有统计学意义(P<0.05),两组相对室壁厚度(RWT)相比没有明显的差异(P>0.05).心脏功能指标:左室射血分数(LVEF),左室短轴缩短率(FS),二尖瓣口舒张早期和晚期最大血流速度比(E/A)值较对照组明显增高(P<0.05).结论 缬沙坦可以改善MHD患者的心脏结构和功能.

Abstract

Objective To study valsartan on cardiac (unction and structure in maintenance hemodialysis (MHD) patients. Methods 100 MHD patients were randomized into valsartan group and control group. Patients in the valsartan group were given 80mg valsartan per day for six months. Before and after the treatment, cardiac structure echo-cardiography Index: Left atrial end systolic diameter (LADs), left ventricular end diastolic diameter (LVEDd), tn-terventricular septum diastolic thickness (IVSTd), left ventricular posterior wall diastolic thickness (LVPWTd), left atrial diameter index (LAI), left ventricular mass index ( LVMI), relative wall thickness (RWT), cardiac function parameters: the cardiac function parameters, such as left ventricular ejection fraction (LVEF), left ventricular fractional shortening (KS) .mitral early and late diastolic peak velocity ratio (E/A) .were detected with echocardio-graphy. The data were statistically analyzed through SPSS16. 0. Results After 6 months, MHD patients with the treatment group cardiac structure indicators:LADs, LVEDd, IVSTd, LVPWTd, LAI, LVMI values were significantly lower than the control group,the difference was significant (P<0. 05), RWT had no significant difference) P >0. 05). Indicators of cardiac function: LVEF, FS, E/A values were significantly higher than the control group, the difference was significant (P <0. 05). Conclusions Valsartan can improve cardiac function and structure in MHD patients, and maybe contribute to the prevention and treatment of cardiovascular complications in MHD patients.

关键词

四唑类/缬氨酸/类似物和衍生物/肾透析/心脏/药物作用

Key words

Tetrazolcs/Valine/analogs & derivatives/Renal Dialysis/Heart/drug effects

引用本文复制引用

出版年

2012
中国误诊学杂志
中华预防医学会 漯河市中心医院 重庆第九人民医院

中国误诊学杂志

影响因子:0.406
ISSN:1009-6647
参考文献量6
段落导航相关论文